Research Analysts Set Expectations for Corium International, Inc.’s FY2022 Earnings (CORI)
Corium International, Inc. (NASDAQ:CORI) – Research analysts at Jefferies Group issued their FY2022 EPS estimates for Corium International in a report released on Friday. Jefferies Group analyst D. Steinberg expects that the biopharmaceutical company will post earnings of $0.86 per share for the year. Jefferies Group has a “Buy” rating and a $10.00 price objective on the stock.
Several other analysts also recently commented on CORI. BidaskClub cut shares of Corium International from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. ValuEngine cut shares of Corium International from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Needham & Company LLC reiterated a “buy” rating and issued a $13.00 price objective on shares of Corium International in a research note on Sunday, September 17th. HC Wainwright initiated coverage on shares of Corium International in a research note on Tuesday, September 26th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $12.00 price objective on shares of Corium International in a research note on Wednesday, September 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $13.38.
TRADEMARK VIOLATION WARNING: “Research Analysts Set Expectations for Corium International, Inc.’s FY2022 Earnings (CORI)” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/research-analysts-set-expectations-for-corium-international-inc-s-fy2022-earnings-cori/1718597.html.
Corium International (CORI) traded up $0.39 during trading hours on Monday, hitting $11.34. 302,394 shares of the stock were exchanged, compared to its average volume of 183,553. The company has a current ratio of 7.04, a quick ratio of 6.80 and a debt-to-equity ratio of 1.89. Corium International has a 12-month low of $2.67 and a 12-month high of $12.18.
In other news, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of Corium International stock in a transaction on Friday, November 17th. The stock was sold at an average price of $10.96, for a total transaction of $5,480,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 868,100 shares of company stock valued at $9,538,781. Corporate insiders own 45.70% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its holdings in Corium International by 161.8% in the second quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock worth $494,000 after purchasing an additional 40,891 shares in the last quarter. EAM Investors LLC bought a new position in Corium International in the second quarter worth about $563,000. Stonepine Capital Management LLC bought a new position in Corium International in the second quarter worth about $3,085,000. Teachers Advisors LLC bought a new position in Corium International in the second quarter worth about $272,000. Finally, TIAA CREF Investment Management LLC bought a new position in Corium International in the second quarter worth about $411,000. Hedge funds and other institutional investors own 89.96% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.